Prostate Cancer

In the second article of a 2-part series, Mehmet A. Bilen, MD, explains how further findings from the phase 3 CARD trial support the wider role cabazitaxel should have in treating patients with metastatic castration-resistant prostate cancer.

Following positive results from cohorts 1 and 2 of the SECuRE trial, dosing of 64Cu/67Cu SAR-bisPSMA has begun in patients with metastatic castration-resistant prostate cancer in cohort 3.

During a Targeted Oncology™ Case-Based Roundtable™ event, Atish D. Choudhury, MD, PhD, and Alicia Morgans, MD, MPH, discussed with participants about selecting next-line therapy for metastatic castration-resistant prostate cancer after use of enzalutamide and docetaxel.

The metastasis-free survival benefit of enzalutamide, and other efficacy and safety data are now under FDA review for the potential approval of the drug for patients with non-metastatic castration-sensitive prostate cancer.

A primary end point has been met in the phase 3 CONTACT-02 clinical trial.

At a live virtual event, Rahul Aggarwal, MD, discussed the addition of olaparib to the treatment of patients with metastatic castration-resistant prostate cancer harboring certain gene mutations.

Daniel P. Petrylak, MD, highlights data from the phase 3 KEYNOTE-921 of pembrolizumab in combination with docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer.

In the first article of a 2-part series, Mehmet A. Blien, MD, discusses where cabazitaxel fits into the treatment paradigm for patients with metastatic castration resistant prostate cancer.

Andrew J. Armstrong, MD, ScM, discusses the methods behind a study that established a digital pathology biomarker for the benefit of androgen deprivation therapy in localized high-risk prostate cancer.

Results from the phase 3 MAGNITUDE study have led to a quick FDA decision on the future of a dual action tablet for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer.

Alicia K. Morgans, MD, MPH, discusses real-world evidence the shows patients with non-metastatic castration resistant prostate cancer on darolutamide have a longer time till discontinuation when compared with enzalutamide and apalutamide.

Daniel J. George, MD, offers closing thoughts and advice to community oncologists who treat patients with prostate cancer.

Clinical insights on managing adverse events associated with PARP inhibitor therapy in patients with prostate cancer.

Daniel J. George, MD, provides insights on how to treat patients with prostate cancer who have pathogenic non-BRCA HRD mutations, and his approach when patients progress on a PARP inhibitor.

A medical oncologist discusses situations in which he might recommend abiraterone alongside a PARP inhibitor as first-line treatment for patients with mCRPC.

Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted pet imaging agent in prostate cancer. The agent has now been added to the NCCN guidelines.

Initial data from the phase 1/2 APEX-01 trial support the FDA’s fast track designation for ARX517 in patients with metastatic castration-resistant prostate cancer.

In the second article of a 2-part article series, Joshua Lang, MD, and live event participants discuss the role of cabazitaxel for the treatment of patients with prostate cancer who harbor certain mutations or have other factors that make their disease unique.

On the heels of an ASCO presentation of data from the phase 3 TALAPRO-2 trial, the FDA has granted approval to the study combination for the treatment of a metastatic castration-resistant prostate cancer subgroup.

In the first of a 2-part article series, Joshua Lang, MD, and live event participants discuss how the addition of cabazitaxel to the treatment of patients with metastatic castration-resistant prostate cancer can improve outcomes despite some challenging adverse events.

Comprehensive insight on the real-world use of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer management, given patient, disease, and logistical concerns.

Key opinion leader Alicia Morgans, MD, MPH, considers the role of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer management.

Expert perspectives on the VISION and TheraP trials, which utilized lutetium Lu 177 vipivotide tetraxetan, also known as lutetium-177–PSMA-617, in the setting of metastatic castration-resistant prostate cancer.

Focused discussion on the CARD trial, which utilized cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer.